Renal Disease Equation Research Articles

Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study.

To determine the safety and efficacy of human chorionic gonadotropin hormone-derivative EA-230 in cardiac surgery patients. Cardiac surgery induces systemic inflammation and may impair renal function, affecting patient outcome. EA-230 exerted immunomodulatory and renoprotective effects in preclinical models and was safe and showed efficacy in phase I and II human studies. Double-blinded, placebo-controlled, randomized study. Collaboration of the Cardiothoracic Surgery, Anesthesiology, and the Intensive Care departments of a tertiary hospital in the Netherlands. One hundred eighty patients undergoing an on-pump coronary artery bypass procedure with or without concomitant valve surgery. Ninety mg/kg/hr EA-230 or placebo administered during surgery. During the study, no safety concerns emerged. EA-230 did not modulate interleukin-6 plasma concentrations (area under the curve 2,730 pg/mL × hr [1,968-3,760] vs 2,680 pg/mL × hr [2,090-3,570] for EA-230 and placebo group, respectively; p = 0.80). Glomerular filtration rate increased following surgery (mean ± sem increase in the EA-230 vs placebo groups: glomerular filtration rateiohexol measured using iohexol plasma clearance: 19 ± 2 vs 16 ± 2 mL/min/1.73 m2; p = 0.13 and estimated glomerular filtration rate with the Modification of Diet in Renal Disease equation using creatinine: 6 ± 1 vs 2 ± 1 mL/min/1.73 m2; p = 0.01). The "injury" stage of the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease criteria for acute kidney injury was 7% in the EA-230 group versus 18% in the placebo group (p = 0.07). In addition, EA-230-treated patients had a less positive fluid balance compared with placebo-treated patients (217 ± 108 vs 605 ± 103 mL; p = 0.01), while the use of vasoactive agents was similar in both groups (p = 0.39). Finally, hospital length of stay was shorter in EA-230 treated patients (8 d [7-11] vs 10 d [8-12]; p = 0.001). Efficacy results were more pronounced in patients that had longer duration of surgery and thus longer duration of study drug infusion. EA-230 was safe in patients undergoing on-pump cardiac surgery. It did not modulate interleukin-6 plasma concentrations but appeared to exert beneficial renal and cardiovascular effects and shortened in-hospital length of stay.

PLASMA XANTHINE OXIDASE ACTIVITY IS ASSOCIATED WITH LOW ESTIMATED GLOMERULAR FILTRATION RATE IN NEWLY DIAGNOSED HYPERTENSIVES

Abstract Objective: Elevated circulating uric acid level has emerged as an independent predictor of adverse outcomes in hypertension. Increased reactive oxygen species that could be caused by increased activity of xanthine oxidase (XO) during the production of uric acid has been attributed to hypertension. However, the predictive value of XO on impaired glomerular filtration rate in hypertension is unknown. The present study aims at evaluating the correlations between plasma uric acid concentration and XO activity, and estimated glomerular filtration rate (eGFR) in newly diagnosed non-diabetic hypertensive subjects. Design and method: Cross-sectional analyses were performed in treatment-naïve hypertensives with blood pressure equals to or more than 140/90 mmHg (n = 46) and normotensive with blood pressure equals to or less than 120/80 mmHg (n = 17), who were without history of diabetes mellitus, hyperlipidemia, smoking, thyroid disease and insulin or steroid use. Both groups were matched for age, sex and BMI. Using the modification of diet in renal disease equation, individuals with < median value of 91 ml/min/1.73 m2 were considered to have impaired eGFR. Results: Our results showed that hypertensives had higher uric acid level than the normotensives. Activity of XO was comparable in both the hypertensives and normotensives. Interestingly, hypertensives or normotensives with impaired eGFR had higher (p < 0.0001) XO activity than those with normal eGFR. Using multivariate regression analysis, results showed that XO activity (beta = 0.277; p < 0.0001) was an independent determinant of impaired eGFR in hypertensives only. The receiver operating characteristic curve analysis also showed that plasma XO activity (0.699) was a better predictor of impaired eGFR in hypertensives than plasma uric acid. Conclusions: These results demonstrate that plasma XO activity is significantly associated with low eGFR in hypertensives, independently of plasma uric acid level. The findings could imply that elevated plasma activity of XO may be a stronger risk factor that would promote the development of hypertension-related renal dysfunction.

THE RELATIONSHIP BETWEEN ATRIAL FIBRILLATION AND RENAL DYSFUNCTION

Objective: Lately, interrelation between atrial fibrillation (AF) and chronic kidney disease (CKD) has received increasing attention, owing to the collective risk factors. The aim of this study, was to appreciate the severity of the renal dysfunction depending on the temporal pattern of atrial fibrillation in patients presenting both conditions. Design and method: We retrospectively analyzed 258 atrial fibrillation patients, mean age 73.48 yr (SD= 10.4), 51.6% females, presenting different stages of chronic kidney disease. The study population was divided in three groups based on the presentation and duration of AF: paroxysmal, persistent and permanent. In order to quantify the severeness of the CKD, we estimated the glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation. Results: Related to the type of atrial fibrillation, 38% of patients had paroxysmal AF, 3.9% persistent AF, respectively 58.1% had permanent AF. Regarding the mean value of the eGFR, in the paroxysmal AF group we obtained a mean value of 69.06 ml/min/1.73 (median= 67.5, SD= 33.54) while in the persistent AF group the mean eGFR value was 70.9 ml/min/1.73 (median= 67.5, SD= 31.2) and in the group of permanent AF, the mean value was 61.2 ml/min/1.73 (median= 55.5, SD= 30.26). Therefore, no statistically significant difference (p = 0.6262) was obtained in terms of the severity of renal dysfunction compared to the type of atrial fibrillation. Conclusions: Our findings demonstrate that neither type of AF is predisposing to more severe outcome of chronic kidney disease. On the other hand, independent of atrial fibrillation type, the eGFR is an important monitoring tool of CKD progression in atrial fibrillation patients. Overall, due to increasingly occurrence of atrial fibrillation with chronic kidney disease, further studies are required in order to streamline their management, taking into account renal function in determining cardioembolic risk as well.

RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND RENAL FUNCTION DETERMINED BY CKD-EPI AND MDRD EQUATIONS IN A CHINESE COHORT UNDERGOING HEALTH ASSESSMENT

Objective: The relationship between the renal function and large arteries remains to be determined. Our study investigated the relationship between carotid-femoral pulse wave velocity (c-fPWV) as a measure of arterial stiffness and renal function in healthy participants. Design and method: Our cross-sectional study was conducted in healthy individuals in China. We enrolled participants from January 2017 to June 2019. c-fPWV and blood pressure were measured and blood samples taken in all participants. Estimated glomerular filtration rate (eGFR) was evaluated by four different formulae using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) equations: (i) CKD-EPICr formula based on Cr, (ii) CKD-EPICysC formula based on CysC, (iii) CKD-EPICrCysC formula based on Cr andCysC, (iv) MDRD. Results: Average age of 431 study participants was 53.1 ± 13.0 years (68.1% male), 23.7% had diabetes mellitus, 66.6% had hypertension. The average eGFR values of CKD-EPICr, CKD-EPICysC, CKD-EPICrCysC and MDRD equations were respectively 91.9 ± 15.6, 86.8 ± 21.4, 89.6 ± 18.3 and 90.7 ± 16.6 ml/min·1.73m2. c-fPWV was significantly and negatively correlated with eGFR of CKD-EPICr (r = -0.336), CKD-EPICysC (r-0.385), CKD-EPICrcysC (r = -0.378) and MDRD (r = 0.219) equations. After adjusting for confounding factors, c-fPWV remained significantly and negatively correlated with eGFR evaluated by CKD-EPICysC equation (β=-0.118), and significantly and positively correlated with age (β = 0.347), SBP (β= 0.275), HR (β = 0.086), FPG (β= 0.098). Conclusions: In normal individuals in China, c-fPWV is negatively correlated with eGFR evaluated in different four equations, however only the equation of CKD-EPICysC showed an independent relation with c-fPWV.

IMPACT OF CHRONIC KIDNEY DISEASE ON HEART FAILURE SEVERITY IN HYPERTENSION AND ATRIAL FIBRILLATION PATIENTS

Objective: Given the frequent association of chronic kidney disease (CKD) to cardiovascular disorders and the coexistence of heart failure (HF) with atrial fibrillation (AF), especially in elderly, hypertension being a contributor, our main objective was to assess the effect of kidney dysfunction on the heart failure progression in hypertension and atrial fibrillation patients. Design and method: We conducted a retrospective analytic-observational study that included 258 AF patients, mean age 73.48 yr (SD = 10.4), 51.6% females. In order to classify the CKD, we divided the study population in two groups based on the estimated glomerular filtration rate (eGFR): higher or equal than 60, respectively below 60 ml/min/1.73 square meters, comparing the estimations of Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. We used the NYHA classification to identify the HF severity. Results: Of all patients, according to the presence or absence of the hypertension, 210 patients (81.4%) presented high blood pressure values. In terms of the eGFR using the MDRD equation, 117 patients presented a value higher or equal than 60 ml/min/1.73 square meters, while 93 had an eGFR below 60 ml/min/1.73 square meters. The median value of NYHA class was 3 in both groups (SD = 1.03; 0.96) and there was no statistical significance (p = 0.13) between them. By comparison, estimation using the CKD-EPI equation, indicated a statistically significant difference (p = 0.03), 109 patients presented higher than 60 ml/min/1.73 square meters and 101 patients were below this cut off value even though the median NYHA class was 3 as well (SD = 1.04; 0.94). Conclusions: These results reinforce the well-known superiority in the accuracy of the CKD-EPI equation. But, in terms of the influence of renal dysfunction severity on the heart failure severeness, our results suggest that decreasing in the eGFR is not correlated with the progression of the heart failure in AF patients. However, given the severity of complications and importance of proper treatment in atrial fibrillation, the development of an estimation equation that relates to the presence of atrial fibrillation should be considered.

Evaluation of glomerular filtration rate using iohexol plasma clearance in critically ill patients with augmented renal creatinine clearance: A single-centre retrospective study.

Augmented renal creatinine clearance (ARC) (≥130 ml min-1 1.73 m-2) is frequent in intensive care unit (ICU) patients and may impact patient outcome. To compare glomerular filtration rate (GFR) measured with iohexol plasma clearance and creatinine clearance in critically ill patients with augmented renal clearance. Single-centre, retrospective study. French University Hospital ICU from November 2016 to May 2019. Adult patients with augmented renal clearance who had a measurement of iohexol plasma clearance. Agreement between 6 h creatinine clearance (6 h CrCl) and iohexol plasma clearance (GFRio). Twenty-nine patients were included. The median 6 h creatinine clearance was 195 [interquartile range (IQR) 162 to 251] ml min-1 1.73 m-2 and iohexol clearance was 133 [117 to 153] ml min-1 1.73 m-2. Sixteen patients (55%) had hyperfiltration (clearance >130 ml min-1 1.73 m-2) measured with iohexol clearance. Mean bias between iohexol and creatinine clearance was -80 [limits of agreement (LoA) -216 to 56 ml min-1 1.73 m-2]. For Cockcroft and Gault Modification of Diet in Renal Disease equation (MDRD), Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) formulae, mean biases were, respectively -27 (LoA -99 to 45), -14 (LoA -86 to 59) and 15 (LoA -33 to 64) ml min-1 1.73 m-2. In the present study, we found that in patients with augmented renal creatinine clearance, half of the patients do not have hyperfiltration using iohexol clearance measurements. We observed an important bias between 6 h CrCl and GFRio with large LoA. In critically patients with ARC, 6 h CrCl does not reliably estimate GFR and 6 h CrCl nearly systematically overestimates renal function. Comparison of creatinine-based GFR estimations and GFRio show acceptable bias but wide LoA.

The association of estimated glomerular filtration rate with outcomes following infrainguinal bypass for peripheral arterial disease

ObjectiveChronic kidney disease (CKD) is a recognized predictor of long-term survival, frequently coexisting with peripheral arterial disease (PAD). Estimated glomerular filtration rate (eGFR) is a more accurate marker of renal function than creatinine. This study sought to determine the graded impact of CKD, defined by eGFR, on infrainguinal lower extremity bypass (LEB) outcomes. MethodsThis retrospective study examined 44,332 patients from the Vascular Quality Initiative database who underwent LEB between January 2003 and November 2019. The GFR was estimated using the Modification of Diet in Renal Disease equation. Multivariable logistic regression was used to study perioperative mortality and Kaplan-Meier survival estimation and multivariable Cox regression were used to evaluate 5-year mortality, 1-year major amputation, and major amputation/death. ResultsThe 30-day mortality odds was increased for CKD 3 (odds ratio [OR], 1.58; 95% confidence interval [CI], 1.32-1.91; P < .001) and CKD 5 (OR, 3.08; 95% CI, 2.45-3.87; P < .001) relative to CKD 1 to 2. Comparing CKD stages 3, 4, and 5 with CKD 1 and 2, there was a stepwise increase in the adjusted hazard of 5-year mortality (hazard ratio [HR], 1.18; 95% CI, 1.09-1.27; P < .001), (HR, 1.73; 95% CI; 1.47-2.03; P < .001) and (HR, 2.58; 95% CI, 2.33-3.84; P < .001), respectively. Although the risk of 1-year death or major amputation did not differ for CKD 3 compared with CKD 1, this was 50% higher for CKD 4 (HR, 1.50; 95% CI, 1.26-1.78; P < .001) and doubled for CKD 5 (HR, 2.07; 95% CI, 1.87-2.29; P < .001) compared with CKD 1 and 2. The adjusted HR for major amputation in 1 year was 0.81 (95% CI, 0.71-0.92; P = .002), 1.14 (95% CI, 0.84-1.54; P = .396) and 1.56 (95% CI,1.31-1.84; P < .001) for CKD 3, 4, and 5, respectively, compared with CKD 1 and 2. ConclusionsThe estimated GFR is a useful predictor of postoperative mortality, overall survival, and/or amputation after LEB in patients with PAD. It should be considered in the preoperative risk-benefit analysis process to guide patient selection in the population with concomitant PAD and CKD being considered for LEB.

The paradoxical relationship between severity of cerebral palsy and renal function in middle-aged adults: better renal function or inappropriate clinical assessment?

Purpose To determine the association between severity of cerebral palsy with serum creatinine (sCr) and sCr-based equations to estimate glomerular filtration rate (eGFR), a marker of renal function. Methods A clinic-based sample of 30–64 year-olds with cerebral palsy was examined and stratified by motor impairment: gross motor function classification system (GMFCS) I/II (n = 79), GMFCS III (n = 78), and GMFCS IV/V (n = 137). sCr, which is influenced by muscle mass, was obtained and sCr-based eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. Results sCr was lower with increasing GMFCS. The opposite pattern was observed for eGFR: GMFCS IV/V had significantly higher eGFR derived from MDRD compared to other GMFCS groups; GMFCS III had significantly higher eGFR compared to GMFCS I/II. The pattern was similar for CKD-EPI derived eGFR. Conclusions According to widely used clinical assessment methods for renal function, higher severity of cerebral palsy among adults is associated with better renal function, which is incongruent with their other biological systems. This paradoxical relationship is likely driven by lower muscle rather than true renal function, and thus, sCr-based eGFR may overestimate renal function, especially for GMFCS IV/V. Further prospective studies are needed. Implications for rehabilitation Common methods of clinical assessment may over-estimate renal function for adults with cerebral palsy (CP), potentially giving a false positive for normal renal health due to their reliance on muscle mass. This study of a clinic-based sample of middle-aged adults with CP highlights the paradoxical relationship between severity of CP and renal function, which is likely driven by methodological limitations in the presence of low muscle mass rather than actual better renal function. It is recommended that clinicians have a high suspicion of abnormal renal function and the need for a nephrology consultation, especially with changes in creatinine levels, even within the normal range. Rehabilitation for adults with CP must have a strong focus on muscle and kidney health, especially for patients with more severe forms of CP.

Prevalence and associated factors of impaired renal function and albuminuria among adult patients admitted to a hospital in Northeast Ethiopia.

Chronic kidney disease (CKD) is increasingly common in hospitalized patients and is associated with increased risk for in-hospital morbidity and mortality. However, data regarding the prevalence of CKD in the African hospitalized patient population are limited. We therefore examined the prevalence and associated factors of impaired renal function and albuminuria among adult patients admitted to the internal medicine wards of a hospital in Northeast Ethiopia. A cross-sectional study was conducted from January 1 to April 30, 2020 at the inpatient settings of Dessie referral hospital. Data on demographics and medical history were obtained, and serum creatinine and albuminuria were analyzed. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation. CKD was defined as impaired eGFR (<60 ml/min/1.73m2) and/or albuminuria. Univariate and multivariable analysis were conducted to determine factors associated with impaired eGFR and albuminuria. A total of 369 patients were included in this study. The prevalence of impaired eGFR was 19.0% (95%CI: 15.2%-23.2%) and albuminuria was 30.9% (95%CI: 26.3%-35.7%). Overall, 33.9% (95%CI: 29.2%-38.9%) of the patients had some degree of CKD, but only 21.6% (95%CI: 15.1%-29.4%) were aware of their renal disease. In multivariable analysis, older age, a family history of kidney disease, diabetes, hypertension and HIV were independently associated with both impaired eGFR and albuminuria while male gender was independently associated with only albuminuria. CKD is common in adult patients admitted to the internal medicine wards, but only few patients are aware of their condition. These findings highlight the need for feasible approaches to timely identify kidney disease and raise awareness on the importance of detection and early intervention in the inpatient settings.

Renal function in a cohort of HIV-infected patients initiating antiretroviral therapy in an outpatient setting in Ethiopia.

To evaluate the prevalence and associated factors of abnormal renal function among Ethiopian HIV-infected patients at baseline prior to initiation of antiretroviral therapy (ART) and during follow-up. We conducted a retrospective observational cohort study of HIV infected patients who initiated ART at the outpatient ART clinic of Mehal Meda Hospital of North Shewa, Ethiopia from January 2012 to August 2018. Demographic and clinical data were abstracted from the medical records of patients. Renal function was assessed by estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation. Univariate and multivariate analysis were conducted to determine the factors associated with abnormal renal function at baseline and during follow-up. Among 353 patients, 70 (19.8%) had baseline eGFR <60 ml/min/1.73m2 and 102 (28.9%) had eGFR = 60-89.9 ml/min/1.73m2. Factors associated with baseline renal impairment (eGFR <60 ml/min/1.73m2) included female sex (AOR = 3.52, CI 1.75-7.09), CD4 count < 200 cells/mm3 (AOR = 2.75, CI 1.40-5.42), BMI < 25 Kg/m2 (AOR = 3.04, CI 1.15-8.92), low hemoglobin (AOR = 2.19, CI 1.16-4.09) and high total cholesterol (AOR = 3.15, CI 1.68-5.92). After a median of 3.0 years of ART, the mean eGFR declined from 112.9 ± 81.2 ml/min/1.73m2 at baseline to 93.9 ± 60.6 ml/min/1.73m2 (P < 0.001). The prevalence of renal impairment increased from 19.8% at baseline to 22.1% during follow-up. Of 181 patients with baseline normal renal function, 49.7% experienced some degree of renal impairment. Older age (AOR = 3.85, 95% CI 2.03-7.31), female sex (AOR = 4.18, 95% CI 2.08-8.40), low baseline CD4 (AOR = 2.41, 95% CI 1.24-4.69), low current CD4 count (AOR = 2.32, 95% CI 1.15-4.68), high BMI (AOR = 2.91, 95% CI 1.49-5.71), and low hemoglobin (AOR = 3.38, 95% CI 2.00-7.46) were the factors associated with renal impairment during follow-up. Impaired renal function was common in HIV-infected patients initiating ART in an outpatient setting in Ethiopia, and there appears to be a high prevalence of renal impairment after a median ART follow-up of 3 years. There is a need for assessment of renal function at baseline before ART initiation and regular monitoring of renal function for patients with HIV during follow-up.

Kidney Dysfunction among COVID-19 Patients in the United Arab Emirates.

ObjectivesWe sought to determine the estimated glomerular filtration rate (eGFR) among patients with COVID-19 and to examine its correlation with different demographic, clinical, and laboratory characteristics.MethodsThis study examined patients diagnosed with COVID-19 and enrolled at Al Kuwait Hospital, Dubai, UAE. eGFR was calculated using the Modification of Diet in Renal Disease equation, 186 × (SCr mg/dL)-1.154 × (age)-0203 × 0.742 [if female] × 1.212 [if black], and compared for 250 COVID-19 cases and 153 non-COVID-19 controls. Analysis were performed using univariate statistics.ResultsThe overall mean age of the cohort was 47.2±14.0 years, and 54.6% (n = 220) were males. The results showed that 45.3% of COVID-19 patients had mild-severe renal impairment, as reflected in the eGFR. When compared to patients with normal eGFR, those with severe renal impairment were older (62.5 vs. 40.2 years; p < 0.001), more likely to be male (100% vs. 71.1%; p = 0.016), and have comorbidities (90.9% vs. 40.0%; p < 0.001) including diabetes mellitus (72.7% vs. 21.5%; p < 0.001) and hypertension (72.7% vs. 25.2%; p = 0.003). They were also more likely to be associated with those that had severe (36.4% vs. 25.9%; p < 0.001) and critical (63.6% vs. 16.3%; p < 0.001) COVID-19 infection as well as intensive care unit admission (72.7% vs. 16.3%; p < 0.001). Correlational analysis showed a significant association between renal function indicators and different laboratory markers, including hematological indices and different liver enzymes.ConclusionsThis is the first study to examine the renal function among COVID-19 cases in the Middle East. Nearly half of COVID-19 patients had moderate to severe renal impairment. Diabetes mellitus and hypertension were the most common underlying comorbidities associated with moderate-severe renal function impairment among COVID-19 patients.

Role of Renal Dysfunction as a Prognostic Factor in Acute Stroke Patients at a Tertiary Hospital in Northeastern Nigeria.

Chronic kidney disease (CKD) and stroke share many common risk factors, and the presence of CKD confers added risk factors for stroke. With increasing interest and understanding of the close relationship between the kidney and the brain, this study aims to assess the prevalence and impact of renal dysfunction on outcomes acute stroke patients. This is a prospective hospital-based study carried out in the neurology unit of University of Maiduguri Teaching Hospital, Maiduguri, northeastern Nigeria. The study population consisted of adult patients (>18 years) admitted in the medical wards with a diagnosis of acute stroke. Sociodemographic variables and biochemical parameters were obtained from each patient. Patients' functional status assessment by modified Rankin scale, Barthel index, and National Institutes of Health Stroke Scale score were obtained at admission and discharge. Glomerular filtration rate (GFR) was calculated using the modification of diet in renal disease equation. Patients who have estimated GFR (eGFR) <60 mL/min/1.73 m2 were considered to have CKD. Patients were grouped into A: with GFR <60 mL/min and B: GFR >60 mL/min. Out of a total of 501 patients admitted during the study period, 448 patients had complete data and were recruited, out of which 275 (61.4%) were male and 173 (38.6%) were female. Their ages ranged from 38 to 89 years, with a mean age ± standard deviation of 53.85 ± 18.13 years. The mean eGFR of the study population was 66.55 ± 30.49 mL/min. Two hundred and twenty-five (50.2%) had renal dysfunction with GFR <60 mL/min. The mean GFR of patients with renal dysfunction was 32.84 ± 27.59 mL/min, and patients without renal dysfunction had a mean GFR of 73.68 ± 35.61 mL/min. Patients with renal dysfunction on admission had Barthel stroke score of 20.74 ± 18.74 as compared to patients without renal dysfunction (25.49 ± 20.34), P = 0.017. At discharge, the Barthel scores for the two groups were 53.87 ± 30.17 and 41.71 ± 30.29 (P = 0.000), respectively. Patients with renal dysfunction had longer hospital stay with a mean duration on admission of 45.66 ± 39.90 days and severe residual disability at discharge. Acute stroke patients who have associated renal dysfunction have severe disability on admission and discharge. Renal dysfunction is common among acute stroke patients.

Role of Computed Tomography in Estimation of Residual Renal Function at One Year after Donor Nephrectomy: Comparison with Nuclear Scintigraphy.

Computed tomography (CT) is routinely used for preoperative anatomical evaluation of renal donors, but recent studies show that it may be useful as a predictor of renal function too. This study aimed to compare CT volumetry-attenuation-based glomerular filtration rate (GFR) with Tc99m-diethylene-triamine-pentaacetic acid (DTPA) renal scintigraphy GFR and predict post-donor nephrectomy renal function. This is a prospective study involving 39 renal donors at a tertiary care hospital in northern India from 2014 to 2017. Renal volume and attenuation were determined by CT using a semiautomatic tool, and split renal function (SRF) was calculated for each side. CT-GFR was obtained using CT-SRF and global GFR from modification of diet in renal disease equation. At 12 months after nephrectomy, GFR was estimated from serum creatinine (eGFR). Predonation CT-GFR of preserved kidney was used to predict post-nephrectomy renal function which was compared with post-donation renal function calculated using serum creatinine as well as with DTPA-GFR. Pearson correlation coefficient and scatter diagram were used to assess and test the linear relationship between two continuous variables. The Statistical Package for the Social Sciences, version 23, was used for data analysis. There was a highly significant change in mean DTPA-GFR and mean CT-GFR compared to eGFR values (50.79-64.25, 26.50%, and 50.77-64.25, 26.55%, respectively). Similarly, there was a very good correlation between DTPA-GFR and eGFR (r = 0.968, P <0.001) as well as CT-GFR and eGFR (r = 0.968, P <0.001). CT volumetry-attenuation-based GFR accurately predicts post-donor nephrectomy renal function at 1 year similar to Tc99m-DTPA renal scintigraphy.

An Evaluation of Commonly Used Surrogate Baseline Creatinine Values to Classify AKI During Acute Infection

IntroductionClassification of acute kidney injury (AKI) requires a premorbid baseline creatinine, often unavailable in studies in acute infection.MethodsWe evaluated commonly used surrogate and imputed baseline creatinine values against a “reference” creatinine measured during follow-up in an adult clinical trial cohort. Known AKI incidence (Kidney Disease: Improving Global Outcomes [KDIGO] criteria) was compared with AKI incidence classified by (1) back-calculation using the Modification of Diet in Renal Disease (MDRD) equation with and without a Chinese ethnicity correction coefficient; (2) back-calculation using the Chronic Kidney Disease–Epidemiology Collaboration (CKD-EPI) equation; (3) assigning glomerular filtration rate (GFR) from age and sex-standardized reference tables; and (4) lowest measured creatinine during admission. Back-calculated distributions were performed using GFRs of 75 and 100 ml/min.ResultsAll equations using an assumed GFR of 75 ml/min underestimated AKI incidence by more than 50%. Back-calculation with CKD-EPI and GFR of 100 ml/min most accurately predicted AKI but misclassified all AKI stages and had low levels of agreement with true AKI diagnoses. Back-calculation using MDRD and assumed GFR of 100 ml/min, age and sex-reference GFR values adjusted for good health, and lowest creatinine during admission performed similarly, best predicting AKI incidence (area under the receiver operating characteristic curves [AUC ROCs] of 0.85, 0.87, and 0.85, respectively). MDRD back-calculation using a cohort mean GFR showed low total error (22%) and an AUC ROC of 0.85.ConclusionCurrent methods for estimating baseline creatinine are large sources of potential error in acute infection studies. Preferred alternatives include MDRD equation back-calculation with a population mean GFR, age- and sex-specific GFR values corrected for “good health,” or lowest measured creatinine. Studies using surrogate baseline creatinine values should report specific methodology.

Renal Function among HIV Infected Patients on Combination Antiretroviral Therapy: ALongitudinal Cohort Study

Introduction: A large number of Human Immunodeficiency Virus (HIV) infected patients are taking combination Antiretroviral Therapy (cART) worldwide as it has led to dramatic improvements in them with a decreased viral load as well as an increase in Cluster of Differentiation (CD4+) T cell count. Though the incidence of HIV associated Chronic Kidney Disease (CKD) has decreased with the use of effective cART, the prevalence of End Stage Renal Disease (ESRD) in HIV positive patients has increased due to the risen longevity owing to them. Aim: To study the renal function abnormalities in HIV infected patients and to compare the change in renal function of treatment naïve patients with patients on triple drug regimen (cART). Materials and Methods: This prospective longitudinal cohort study was conducted on 54 Enzyme Linked Immunosorbent Assay (ELISA) positive HIV patients belonging to the age group of 18-70 years of both the genders over a period of two years from August 2017 to September 2019 in MKCG Medical College and Hospital, Berhampur, Odisha, India. Forty nine HIV infected patients naive to cART and five patients on cART for a minimum period of three months were included in this study. All patients were treated with triple therapy regimens of either ZLN (Zidovudine 300 mg+Lamivudine 150 mg+Nevirapine 200 mg) or TLE (Tenofovir 300 mg+Lamivudine 150+Efavirenz 600 mg) daily; in a single dose at bed time. Renal function parameters like serum urea, serum creatinine, Creatinine Clearance (CrCl), estimated Glomerular Filtration Rate (eGFR) and CD4+ T cell count of treatment naive patients were compared with the same patients on cART after six months duration. GFR was calculated by Modification of Diet in Renal Disease (MDRD) equation. Results were analysed using the Statistical Package for the Social Sciences (SPSS) software for Windows Version 17.0. Results: Out of 54 patients, 53.7% (n=29) were males and 46.3% (n=25) were females. The mean CrCl of HIV positive patients on cART (79.09±25.705 mL/min) was higher than treatment naive (69.65±25.506 mL/min) patients and was highly significant (p-value=0.003). The mean eGFR of HIV positive patients on cART (102.711±26.9424 mL/min/1.73 m2) was higher than treatment naïve (90.189±28.2575 mL/min/1.73 m2) patients and was highly significant (p-value=0.003). The mean serum urea of HIV positive patients on cART (25.78± 4.721 mg/dL) was lower than HIV positive treatment naïve (26.19±4.742 mg/dL) patients but was non-significant (p-value=0.640). The mean serum creatinine of HIV positive patients on cART (0.815±0.1393 mg/dL) was lower than HIV positive treatment naïve patients (0.906±0.1687 mg/dL) and was also highly significant (p-value=0.003). The mean CD4+ T cell count of HIV positive patients on cART (401.63±225.816 cells/μL) was higher than HIV positive treatment naïve (287.13±198.263 cells/μL) patients and was very highly significant (p=0.001). Conclusion: Renal impairment (CrCl &lt;60 mL/min) and eGFR (&lt;60 mL/min/1.73 m2) were higher in HIV positive treatment naive patients than those on cART. Radiological parameters like size of the kidney and cortical echogenicity became normal after six months on cART.

Cystatin C-Based Renal Function in Predicting the Long-Term Outcomes of Chronic Total Occlusion After Percutaneous Coronary Intervention.

Renal function estimated by various biomarkers predicting for adverse cardiovascular events has not been well-identified in received percutaneous coronary intervention (PCI) for chronic total occlusion (CTO), the advanced stages of atherosclerosis. We aim to determine whether the serum cystatin C-based-estimated glomerular filtration rate (eGFR) can have an improved predictive value in patients with CTO lesions undergoing PCI as compared with multiple creatinine-based estimates of kidney function. Six hundred and seventy-one patients received CTO PCI were retrospectively included in the study. The eGFR was calculated by modification of diet in renal disease equation for Chinese (cMDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations at baseline, respectively. Then, the cohort was categorized into three groups according to standard KDIGO kidney stages based on eGFR. The primary endpoint was all-cause mortality, and the secondary endpoint was cardiac death. Strikingly, cystatin C-based eGFR showed a better performance with the greater area being under the receiver operating characteristic (ROC) curve (0.73 for all-cause mortality and 0.73 for cardiac death, separately) and a better assessment for survival free from adverse event across renal levels among four eGFR equations. Compared with eGFR calculated by other formulas, serum cystatin C-based eGFR showed the highest prognostic value for both all-cause mortality (adjusted HR 3.6, 95% CI 1.6–8.1, P = 0.002) and cardiac death (adjusted HR 2.9, 95% CI 1.0–8.1, P = 0.028). Moreover, cystatin C-based eGFR significantly improved the risk reclassification of event with a high value of net reclassification improvement and integrated discrimination improvement. This study may prove that cystatin C-based eGFR is a better predictor of both all-cause mortality and cardiac death than other equations in populations with CTO undergoing PCI.

Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis.

The relevance of hemodynamic derangements on the incidence of recurrent acute kidney injury (AKI) and chronic kidney disease (CKD) in patients with cirrhosis is largely unknown. Consecutive patients with cirrhosis with a complete record of baseline hemodynamics were followed for identifying risk factors for the development of recurrent AKI and CKD by using negative binomial regression and competing risk analysis, respectively. Consecutive patients with cirrhosis (n = 2013, age 50.1 ± 11.8 years, 80% male, Child A:B:C percentage 13.7:52.9:33.4, and mean Child‐Turcotte‐Pugh score 8.6 ± 1.8) were enrolled, 893 (44.3%) of whom received beta‐blockers, with 44.2% responders. Prior AKI was noted in 12.4% at enrollment. At a median follow‐up of 379 (interquartile range: 68‐869) days, AKI developed at a rate of 0.37 episodes per person‐year, and 26% patients developed CKD. A lower mean number of AKI episodes (0.05 ± 0.25 vs. 0.42 ± 0.868; P < 0.001), CKD (subdistribution hazard ratio 0.74 [0.54‐1.02]), and mortality (hazard ratio 0.21 [0.06‐0.73]) were observed in beta‐blocker responders. Albuminuria was an independent risk factor for recurrent AKI, CKD, and mortality (P < 0.05). Lower systemic vascular resistance index predicted hemodynamic response (odds ratio 2.04 [1.29‐3.22]), cumulative AKI episodes (ratio of means 0.10 [0.08‐0.14]), and development of CKD (subdistribution hazard ratio 0.70 [0.58‐0.83]). Higher hepatic venous pressure gradient (≥17 mm Hg) predicted AKI episodes (ratio of means 1.76 [1.32‐2.35]) but not CKD. Conclusion: High portal pressure and severe vasodilatation predispose patients with cirrhosis to repeated AKI episodes and development of CKD. Response to beta‐blockers and therapies targeting the vasodilatory state could prevent frequent AKI and the risk of CKD development. Albuminuria could serve as an early marker of renal dysfunction in patients with cirrhosis.

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Background Multiple myeloma (MM) is the second most common hematologic malignancy and is associated with significant patient burden. Renal impairment has been shown to affect up to 50% of patients (pts) with MM. Renal impairment is an independent predictor of poor survival outcomes for pts with MM, with a median survival of approximately half that of pts without renal impairment. Aims To assess change in renal function by treatment line and drug class among pts with MM and renal impairment (defined as eGFR &amp;lt;50 mL/min/1.73 m2 using the Modification of Diet in Renal Disease equation [eGFR-MDRD]), and to assess real-world outcomes by baseline renal status, renal response, and drug class. Methods Using the nationwide Flatiron Health EHR-derived de-identified database based in the United States, we identified MM pts diagnosed and treated between January 2011 and November 2019 who received ≥1 line of MM therapy and had information on race. We assessed the distribution of pts by eGFR-MDRD level at the start of the first and second line of therapy and the distribution of therapy use (ie, proteasome inhibitor [PI], immunomodulatory drug [IMiD], monoclonal antibody [mAb]). We also evaluated overall survival (OS) by treatment line, stratified by eGFR at the start of each treatment line. Complete renal response (CRR) was assessed in pts with eGFR-MDRD &amp;lt;50 mL/min/1.73 m2; using International Myeloma Working Group recommendations, responders were defined as pts with ≥1 eGFR measurement ≥60 mL/min/1.73 m2 during the treatment line. Logistic regression models were used to examine the association between treatment class and complete renal responder status adjusted for other treatment classes received, age, sex, race, practice type, year of therapy line, and cytogenetic risk. Cox proportional hazard models were used to examine OS by treatment and renal response, adjusted for other treatment classes received, age, sex, race, practice type, year of therapy line, and cytogenetic risk. Flatiron Health, Inc., did not participate in the analysis of this data. Results For the 6990 pts included in the analysis, the mean age at start of initial therapy was 68 years, 46% were female, and 17% were Black. At start of treatment lines 1 and 2, approximately 25% had eGFR-MDRD &amp;lt;50 mL/min/1.73 m2. At treatment initiation, pts with renal impairment were older (71 vs 67 years) and were more likely to present with ISS stage III at diagnosis (38% vs 10%). Pts with renal impairment at the start of each treatment line exhibited decreased OS. Among pts with renal impairment, pts with PI use in first (adjusted odds ratio [aOR] 1.36; 95% CI, 1.04-1.77) or second line (aOR 2.09; 95% CI, 1.38-3.16) were significantly more likely to have a CRR than those without PI use. Pts with IMiD use in first (aOR 2.14; 95% CI, 1.68-2.72) and second (aOR 1.61; 95% CI, 1.10-2.36) line were significantly more likely to have a CRR than those without IMiD use. When classified by both PI and IMiD use, pts with both PI and IMiD use were significantly more likely to have a CRR than those without use of either in the first (aOR 2.35; 95% CI, 1.54-3.60) and second line (aOR 3.89; 95% CI, 1.71-8.86). Pts with PI and IMiD use as well as a CRR also had greater OS in the first (adjusted hazard ratio [aHR] 0.52; 95% CI, 0.37-0.73) and second line (aHR 0.53; 95% CI, 0.32-0.88) vs pts without either PI or IMiD use and no CRR. The use of available mAbs in line 1 or line 2 was not significantly associated with renal response. Lower mAb use, especially in earlier treatment lines, prevented further analyses by mAb combination therapies. Conclusion In this study, MM pts with renal impairment were more likely to be older and to present with ISS stage III at diagnosis. Pts with decreased renal function exhibited decreased OS compared with non-renally impaired pts. Pts who were treated with combination therapy that included PIs and IMiDs together in early treatment lines were more likely to have a CRR and OS was prolonged among these pts, highlighting the benefits of combination therapy. These data suggest that treatment inducing a renal response may result in improved outcomes. Future investigations with larger datasets may improve the understanding of the prognostic value of renal impairment and optimal combination treatment regimens for these pts. Disclosures Mikhael: Amgen, Celgene, GSK, Janssen, Karyopharm, Sanofi, Takeda: Honoraria. Singh:Sanofi-Genzyme: Current Employment. Rice:Sanofi: Current Employment.

ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE.

ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE.